申请人:Barba Oscar
公开号:US20090221645A1
公开(公告)日:2009-09-03
Compounds of formula (I) or pharmaceutically acceptable salts thereof, exhibit 5-HT
1A
agonism in addition to noradrenaline reuptake inhibition and optionally also 5-HT reuptake inhibition are useful for the treatment of obesity.
式(I)的化合物或其药学上可接受的盐,除了去甲肾上腺素再摄取抑制外,还表现出5-HT1A受体激动作用,可选地还具有5-HT再摄取抑制作用,适用于肥胖症的治疗。